The rate of adverse events (AEs) related to cemiplimab was 23%, and the rate of AEs related to chemotherapy was 31%. Seven patients discontinued treatment due to an AE, and 4 of these were related ...

Three analysts surveyed by Zacks expected $3.26 billion. Investors need to pay close attention to AES Corp. (AES) stock based on the movements in the options market lately. The majority of the ...

Patients with non-small cell lung cancer (NSCLC) taking bevacizumab biosimilars demonstrated equivalent therapeutic efficacy ...

Tyra Biosciences' TYRA-300 shows promise as an FGFR3 inhibitor with fewer side effects, but mixed market reactions spotlight ...

Columvi plus chemotherapy showed a 41% reduction in the risk of death in the pivotal phase III STARGLO study1,2 DLBCL—an ...

In a live event, Ganesh V. Raj, MD, PhD, discussed the landscape of metastatic hormone-sensitive prostate cancer considering the recent data from the ARANOTE study.

Compass Therapeutics' lead candidate, tovecimig, shows mixed data in various trials, with a significant upcoming phase 3 ...

Abbreviations: AFP, alpha-fetoprotein; CIK, cytokine-induced killer; FOLFOX, fluorouracil, leucovorin, and oxaliplatin; HAIC, hepatic arterial infusion chemotherapy; HBV, hepatitis B virus ... then ...

Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...

Concurrent use with docetaxel, doxorubicin or irinotecan increases the exposure to these chemotherapy drugs. Concurrent use with carbamazepine, phenobarbital and phenytoin decreases sorafenib ...

After hours: 7:59:40 pm GMT-5 ...